Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2025)

Revolution Medicines has reported Accumulated Expenses over the past 7 years, most recently at $209.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $209.3 million for Q4 2025, up 116.67% from a year ago — trailing twelve months through Dec 2025 was $209.3 million (up 116.67% YoY), and the annual figure for FY2025 was $209.3 million, up 116.67%.
  • Accumulated Expenses for Q4 2025 was $209.3 million at Revolution Medicines, down from $256.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RVMD hit a ceiling of $256.5 million in Q3 2025 and a floor of $4.2 million in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $25.5 million (2023), compared with a mean of $53.6 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 79.21% in 2022 and later surged 1244.6% in 2025.
  • Revolution Medicines' Accumulated Expenses stood at $9.9 million in 2021, then skyrocketed by 198.88% to $29.4 million in 2022, then fell by 19.81% to $23.6 million in 2023, then skyrocketed by 309.16% to $96.6 million in 2024, then surged by 116.67% to $209.3 million in 2025.
  • The last three reported values for Accumulated Expenses were $209.3 million (Q4 2025), $256.5 million (Q3 2025), and $114.7 million (Q2 2025) per Business Quant data.